The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.
Testosterone use was also more likely at sites located in the West vs the Northeast and for care received at a community-based outpatient clinic versus a medical center.
Hypogonadal testicular cancer survivors had 15 times higher odds of metabolic syndrome than their eugonadal counterparts.
In type 2 diabetic male patients, a low testosterone level was found to be associated with anemia. These findings are consistent with previous reports.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
Study of older hypogonadal men does not support use of TRT to improve memory, according to researchers.
Older men on TRT versus placebo for 1 year had improved hemoglobin levels and volumetric bone mineral density and estimated bone strength.
In a large study, testosterone replacement therapy was associated with a 33% lower risk of cardiac and stroke events among hypogonadal men.
The normal range for total testosterone is 264 to 916 ng/dL for healthy men ages 19 to 39 with a body mass index below 30 kg/m2.
Risk peaks in the first 6 months of hormone treatment, but overall odds are low.
Once-daily T-sol administered for 6 months did not indicate new safety concerns, and the outcomes of low sex drive and low energy showed further improvement.
New findings have potential implications regarding patient selection for active surveillance.
The new FDA warning alerts prescribers to the abuse potential of testosterone.
Labeling changes will alert prescribers to the abuse potential of testosterone and the serious adverse effects.
Young men reported improvement in executive function after 2 years of TRT.
Results show that mpMRI and PI-RADSv2 score have a greater ability to detect prostate cancer progression after TRT compared with PSA.
Other risk factors include reduced muscle mass and lower levels of physical activity.
Once-daily 2% testosterone solution safe and effective for sex drive and energy.
Gel hormone treatment led to improved libido, increased sexual activity.
Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.
The finding is from a 30-week study comparing testosterone undecanoate and placebo in hypogonadal men with type 2 diabetes.
Alert patients that use of performance-enhancing drugs can lead to erectile dysfunction and infertility.
In particular, no hepatic toxicities emerged during a 52-week phase 3 trial.
In fact, some data suggest treatment may reduce prostate cancer incidence and aggressiveness.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
Study also identifies clinical characteristics associated with testosterone deficiency in this population.
73% of men in the testosterone group showed improvement in sexual arousal, interest, and drive.
Larger studies and long-term follow-up needed to determine possible risks of treatment.
Increased odds of low testosterone with opioid exposure; increased odds with increasing age, comorbidities.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)